# Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

> **NCT02281318** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 556 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Mepolizumab
- **DRUG:** Placebo
- **DRUG:** SOC

## Key facts

- **NCT ID:** NCT02281318
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-11
- **Primary completion:** 2016-06-10
- **Final completion:** 2016-06-10
- **Target enrollment:** 556 (ACTUAL)
- **Last updated:** 2018-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02281318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02281318, "Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02281318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*